The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
My sentiments exactly.
“So we now know the Mologic biotech is officially recognised by the EU as of today, we ( Omega ) who are using the same passed Biotech are now just waiting on the ‘‘ease of self use trial via Belfast ‘ which was submitted in September
Suggest for shareholders we take a view now on when that will land ? On clearing we enjoy EU HUA”
https://twitter.com/shredz90/status/1468622272617459712?s=21
https://twitter.com/tom_the_bomb__/status/1468656306718453761?s=21
sounds about right to me.
Nb the market has picked up on that fact hence the near 25% jump in the share price
TW, agree
Thinking ….the EU have cleared the biotech of the Omega test - by default we would have used the FIND data
We submitted under EU HUA alongside submitting the Ulster Trial results, which Omega called ‘ the last piece of the Jigsaw’
In effect it’s all down to the engineering element now not the biotech
That’s my view on the current situation
Oke, the usage trials are irrelevant for this list, usage trial were for the HUA for CE,
this list is specifically NOT for home use.
TW, very
Can’t see the buffer/ reagent and even the film being any different that Omega submitted
Omega handled the ‘ ease of use ‘ trial - as we know - which was all about the engineering of the LFT.
It’s good news today that the biotech has cleared, guess it’s all about the EU body satisfied with the Ulster data
Suggest this is our position tonight?
mind you, its hard to argue with a 6p+ rise....nice :)
NT to buy now... 32 close more likely if MMS let it go..
Full ask 30 to buy.
33p coming
SYN - others following you from GDR, compound gains!
Heavy metal buying pressure now, whats happening ???
30 plus today hopefully
and up !!!
oh well thought it sounded to good to be true for odx, down it goes again then......
I flagged some weeks ago that the Mologic Covios test appeared on the "under discussion" list that was published on 10th Nov, so good to see that it has now moved onto the actual approved list that EU govs must select from for professional use government testing. This however is the covois, which is the modified version of the original Mologic test that uses pre-filled buffer. ODX has the revised visitect test. We have no information whether the 2 tests use different parts in the kits. One of the question I asked in the Q&A is whether ODX revised visitect test will be seen as a generic of the Covios test. I suspect it will not.
I note the PD updated their list at the start of the month.
https://www.gov.uk/government/publications/assessment-and-procurement-of-coronavirus-covid-19-tests/outcome-of-the-evaluation-of-rapid-diagnostic-assays-for-specific-sars-cov-2-antigens-lateral-flow-devices
i don't see any additions.
Marcus, thanks for sharing.
One hurdle cleared by default
So we now know the Mologic biotech is officially recognised by the EU as of today, we ( Omega ) who are using the same passed Biotech are now just waiting on the ‘‘ease of self use trial via Belfast ‘ which was submitted in September
Suggest for shareholders we take a view now on when that will land ? On clearing we enjoy EU HUA
"On 21 January 2021, Member States unanimously agreed on a Council Recommendation
setting a common framework for the use of rapid antigen tests and the mutual recognition of
COVID-19 test results across the EU2
. The Council Recommendation called on Member
States to agree on three concrete deliverables:
1. A common list of COVID-19 rapid antigen tests that are considered appropriate for
use in the context of the situations described in the Council Recommendation, that are
in line with countries’ testing strategies.
2. A selection of rapid antigen tests of which Member States will mutually recognise
the test results for public health measures.
3. A common standardised set of data to be included in COVID-19 test result
certificates, further facilitating the mutual recognition of COVID-19 test results."
https://twitter.com/marcus4antonius/status/1468598914353975296?s=20